נק' מוניטין:
58,703
****
1: J Strength Cond Res. 2005 May;19(2):475-80.
A cetylated fatty acid topical cream with menthol reduces pain and improves
functional performance in individuals with arthritis.
Kraemer WJ, Ratamess NA, Maresh CM, Anderson JA, Volek JS, Tiberio DP, Joyce ME,
Messinger BN, French DN, Sharman MJ, Rubin MR, Gomez AL, Silvestre R, Hesslink
RL Jr.
Human Performance Laboratory, Department of Kinesiology, University of
Connecticut, Storrs, Connecticut 06269, USA. [email protected]
This investigation was an extension of a previous study conducted in our
laboratory in which we showed that 1 month of treatment with a topical cream
(Celadrin) consisting of cetylated fatty acids was effective for reducing pain
and improving functional performance in individuals with osteoarthritis (OA) of
the knee (Kraemer et al., Journal of Rheumatology, 2004). We wanted to verify
that the addition of menthol to the compound would produce a similar percentage
of improvement in therapeutic effects. We used a single treatment group with a
pre-post experimental design to examine % treatment changes. Individuals
diagnosed with OA of the knee (N = 10; age, 66.4 +/- 11.5 years) and severe pain
(e.g., OA, rheumatoid arthritis) of the elbow (N = 8; age, 59.1 +/- 18.2 years)
and wrist (N = 10; age, 60.3 +/- 16.8 years) were tested for pain and functional
performance before and after 1 week of treatment with a topical cream consisting
of cetylated fatty acids and menthol applied twice per day. In individuals with
knee OA, significant improvements in stair-climbing ability (about 12%),
"up-and-go" performance (about 12%), balance and strength (about 16.5%), and
range of motion (about 3.5%) were observed, as were reductions in pain. In
individuals with severe pain of the elbow and wrist, significant improvements in
dynamic (about 22 and 24.5%, respectively) and isometric (about 33 and 42%,
respectively) local muscular endurance were observed, as was a reduction in
pain. Neither group demonstrated significant changes in maximal grip strength or
maximal force production. One week of treatment with a topical cream consisting
of cetylated fatty acids and menthol was similarly effective for reducing pain
and improving functional performance in individuals with arthritis of the knee,
elbow, and wrist. The % changes were consistent with our prior work on the
compound without menthol. Further work is needed to determine the impact of
menthol in such a cream. Nevertheless, our data support the use of a topical
cream consisting of cetylated fatty acids (with or without menthol) for
enhancing the potential for exercise training in this population.
Publication Types:
Clinical Trial
PMID: 15903393 [PubMed - indexed for MEDLINE]
2: J Rheumatol. 2002 Aug;29(8):1708-12.
Cetylated fatty acids improve knee function in patients with osteoarthritis.
Hesslink R Jr, Armstrong D 3rd, Nagendran MV, Sreevatsan S, Barathur R.
Hesslink Ventures, San Diego, California, USA.
OBJECTIVE: To determine the benefit of cetylated fatty acids (CFA) on knee range
of motion and function in patients with osteoarthritis (OA). METHODS: Sixty-four
patients with chronic knee OA were evaluated at baseline and at 30 and 68 days
after consuming either placebo (vegetable oil; n = 31) or CFA (Celadrin; n =
33). Evaluations included physician assessment, knee range of motion with
goniometry, and the Lequesne Algofunctional Index (LAI). RESULTS: After 68 days,
patients treated with CFA exhibited significant (p < 0.001) increase in knee
flexion (10.1 degrees) compared to patients given placebo (1.1 degrees). Neither
group reported improvement in knee extension. Patient responses to the LAI
indicated a significant (p < 0.001) shift towards functional improvement for the
CFA group (-5.4 points) after 68 days compared to a modest improvement in the
placebo group (-2.1 points). CONCLUSION: Compared to placebo, CFA provides an
improvement in knee range of motion and overall function in patients with OA of
the knee. CFA may be an alternative to the use of nonsteroidal antiinflammatory
drugs for the treatment of OA.
Publication Types:
Clinical Trial
Randomized Controlled Trial
PMID: 12180734 [PubMed - indexed for MEDLINE]
1: J Strength Cond Res. 2005 May;19(2):475-80.
A cetylated fatty acid topical cream with menthol reduces pain and improves
functional performance in individuals with arthritis.
Kraemer WJ, Ratamess NA, Maresh CM, Anderson JA, Volek JS, Tiberio DP, Joyce ME,
Messinger BN, French DN, Sharman MJ, Rubin MR, Gomez AL, Silvestre R, Hesslink
RL Jr.
Human Performance Laboratory, Department of Kinesiology, University of
Connecticut, Storrs, Connecticut 06269, USA. [email protected]
This investigation was an extension of a previous study conducted in our
laboratory in which we showed that 1 month of treatment with a topical cream
(Celadrin) consisting of cetylated fatty acids was effective for reducing pain
and improving functional performance in individuals with osteoarthritis (OA) of
the knee (Kraemer et al., Journal of Rheumatology, 2004). We wanted to verify
that the addition of menthol to the compound would produce a similar percentage
of improvement in therapeutic effects. We used a single treatment group with a
pre-post experimental design to examine % treatment changes. Individuals
diagnosed with OA of the knee (N = 10; age, 66.4 +/- 11.5 years) and severe pain
(e.g., OA, rheumatoid arthritis) of the elbow (N = 8; age, 59.1 +/- 18.2 years)
and wrist (N = 10; age, 60.3 +/- 16.8 years) were tested for pain and functional
performance before and after 1 week of treatment with a topical cream consisting
of cetylated fatty acids and menthol applied twice per day. In individuals with
knee OA, significant improvements in stair-climbing ability (about 12%),
"up-and-go" performance (about 12%), balance and strength (about 16.5%), and
range of motion (about 3.5%) were observed, as were reductions in pain. In
individuals with severe pain of the elbow and wrist, significant improvements in
dynamic (about 22 and 24.5%, respectively) and isometric (about 33 and 42%,
respectively) local muscular endurance were observed, as was a reduction in
pain. Neither group demonstrated significant changes in maximal grip strength or
maximal force production. One week of treatment with a topical cream consisting
of cetylated fatty acids and menthol was similarly effective for reducing pain
and improving functional performance in individuals with arthritis of the knee,
elbow, and wrist. The % changes were consistent with our prior work on the
compound without menthol. Further work is needed to determine the impact of
menthol in such a cream. Nevertheless, our data support the use of a topical
cream consisting of cetylated fatty acids (with or without menthol) for
enhancing the potential for exercise training in this population.
Publication Types:
Clinical Trial
PMID: 15903393 [PubMed - indexed for MEDLINE]
2: J Rheumatol. 2002 Aug;29(8):1708-12.
Cetylated fatty acids improve knee function in patients with osteoarthritis.
Hesslink R Jr, Armstrong D 3rd, Nagendran MV, Sreevatsan S, Barathur R.
Hesslink Ventures, San Diego, California, USA.
OBJECTIVE: To determine the benefit of cetylated fatty acids (CFA) on knee range
of motion and function in patients with osteoarthritis (OA). METHODS: Sixty-four
patients with chronic knee OA were evaluated at baseline and at 30 and 68 days
after consuming either placebo (vegetable oil; n = 31) or CFA (Celadrin; n =
33). Evaluations included physician assessment, knee range of motion with
goniometry, and the Lequesne Algofunctional Index (LAI). RESULTS: After 68 days,
patients treated with CFA exhibited significant (p < 0.001) increase in knee
flexion (10.1 degrees) compared to patients given placebo (1.1 degrees). Neither
group reported improvement in knee extension. Patient responses to the LAI
indicated a significant (p < 0.001) shift towards functional improvement for the
CFA group (-5.4 points) after 68 days compared to a modest improvement in the
placebo group (-2.1 points). CONCLUSION: Compared to placebo, CFA provides an
improvement in knee range of motion and overall function in patients with OA of
the knee. CFA may be an alternative to the use of nonsteroidal antiinflammatory
drugs for the treatment of OA.
Publication Types:
Clinical Trial
Randomized Controlled Trial
PMID: 12180734 [PubMed - indexed for MEDLINE]
